- Marked weight reduction and favorable metabolic improvements are observed in both men and women.
- Highly consistent efficacy-safety profile across genders, with robust and favorable gastrointestinal tolerability.
On November 15, 2026, Hansoh Pharmaceutical Group Co., Ltd. (“Hansoh Pharmaceutical”, 03692.HK) announced that, at Obesity Week held in Washington, DC, USA on November 14 (US Eastern Time), sex-subgroup analysis data from the Chinese Phase III weight management study(LIGHTEN)of Olatorepatide (HS-20094), a Hansoh Pharma's self-developed dual-biased glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist, was presented as a Late-Breaking Abstract (LBA) poster. Building on the promising full-population data previously released at EASD 2026, this subgroup analysis further disclosed the efficacy and safety profiles among participants of different genders, providing new clinical evidence for individualized weight management in patients with overweight and obesity.

Obesity Week is one of the world’s most authoritative academic conferences in the global field of obesity, co-hosted by The Obesity Society (TOS) and the International Association for the Study of Obesity (IASO). The LBA sessions are dedicated to the latest research of high innovation and major scientific significance. The inclusion of this sex-subgroup analysis of Olatorepatide as an LBA-Poster reflects high recognition by the global metabolism research community of the clinical value of this Chinese original dual-biased GLP1/GIP agonist for weight loss.
LBA-Poster details:
• Presentation Title: Sex-Specific Efficacy of Olatorepatide in Obesity: Greater Response in Women? China Phase 3 Insights[1]
• Session: Diabetes, Weight Management & Sex-Specific Outcomes
• Poster No.: poster-177
• Date/Time: 7:30–8:30 pm ET, November 14, 2026
• Presenter: Linong Ji (Peking University People's Hospital)
Study Methods:
This subgroup analysis was based on the complete dataset of the multicenter, randomized, double-blind, placebo-controlled Phase III trial (LIGHTEN). A total of 604 eligible Chinese adults with overweight or obesity were enrolled. Eligibility required a body mass index (BMI) ≥ 28 kg/m², or BMI between 24 and 28 kg/m² plus at least one weight-related comorbidity. Participants were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous Olatorepatide at 5 mg, 10 mg, 15 mg, or placebo, for 48 weeks of treatment. The subgroup analysis primarily evaluated weight reduction, improvements in metabolic parameters, and safety profiles across male and female participants.
Core Efficacy Data:
After 48 weeks of treatment, Olatorepatide demonstrated statistically significant comprehensive benefits in both male and female participants. Reductions in body weight, waist circumference, waist-to-height ratio (WHtR), and fatty liver index (FLI) across all dose groups were significantly superior to the placebo group, with all between-group p values < 0.001. These findings confirm that Olatorepatide delivers robust weight loss and metabolic improvements in both genders with overweight or obesity.
While both men and women achieved favorable weight loss outcomes, female participants showed numerically greater responses on the above efficacy endpoints, as well as higher achievement rates for weight loss ≥15%, weight loss ≥20%, and waist-to-height ratio <0.5, indicating a trend of superior response among women.
Cross-Gender Safety Data:
No substantive differences in the overall safety profile were observed between the male and female subgroups. All adverse events during treatment were predominantly mild to moderate. Gastrointestinal adverse events(GIAEs) were transient and maintained at low overall incidence rates. Nausea occurred in 9.0% of female participants versus 5.0% of male participants; vomiting occurred in 5.4% of females versus 3.6% of males. The incidence of common GIAEs was substantially lower than the historical publicly available data for approved GLP1 agents. No participants in either gender subgroup discontinued treatment prematurely due to Olatorepatide-related adverse events, demonstrating excellent tolerability and medication adherence in both men and women with overweight or obesity.
The sex-subgroup data of Phase III LIGHTEN trial released at Obesity Week further enriches the evidence base for this Chinese original drug in the management of overweight and obesity across different genders.
About Obesity Week
Obesity Week is the largest and most influential academic conference globally in obesity research. It is co-hosted annually by The Obesity Society and the International Association for the Study of Obesity, bringing together leading researchers, clinicians, and industry practitioners worldwide to share cutting-edge basic research, clinical advances, and public health management experience in obesity. It serves as a core authoritative platform for the release of academic breakthroughs in obesity.
About Olatorepatide Injection
Olatorepatide Injection is a once-weekly subcutaneous dual-biased GLP1/GIP receptor agonist. It functions by modulating metabolic pathways governing appetite regulation, glucose metabolism, and energy balance. Olatorepatide is also currently in Phase III clinical development in China for the treatment of type 2 diabetes mellitus. In June 2025, Hansoh Pharmaceutical entered into a strategic collaboration with Regeneron, granting Regeneron exclusive overseas development and commercialization rights for the asset. In June 2026, the New Drug Application (NDA) for Olatorepatide Injection for long-term weight management in adults with overweight or obesity was accepted for review by the National Medical Products Administration (NMPA) of China.
Reference
[1] Ji, et al. Sex-Specific Efficacy of Olatorepatide in Obesity: Greater Response in Women? China Ph3 Insights. Poster-177, Obesity Week 2026.
About Hansoh Pharma
Statements
Forward-Looking Statements